Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Sell
18
NVO Quote, Financials, Valuation and Earnings
Last price:
$75.34
Seasonality move
:
4.47%
Day range:
$75.52 - $77.29
52-week range:
$73.80 - $148.15
Dividend yield:
1.88%
P/E ratio:
23.41x
P/S ratio:
8.15x
P/B ratio:
17.04x
Volume:
5.9M
Avg. volume:
7.7M
1-year change:
-40.8%
Market cap:
$341.2B
Revenue:
$42.1B
EPS (TTM):
$3.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
$11.5B | $0.80 | 23.17% | 10.71% | $113.54 |
|
ASND
Ascendis Pharma AS
|
$123.2M | -$0.96 | -1.83% | -34.43% | $210.61 |
|
DBVT
DBV Technologies SA
|
$1.1M | -$0.22 | -- | -59.89% | $21.81 |
|
EVAX
Evaxion Biotech AS
|
$1.7M | -$0.15 | 6174.51% | -98% | $13.25 |
|
VKTX
Viking Therapeutics
|
-- | -$0.27 | -- | -21.87% | $99.29 |
|
ZLDPF
Zealand Pharma AS
|
$3.9M | -- | -5.47% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
$76.86 | $113.54 | $341.2B | 23.41x | $0.52 | 1.88% | 8.15x |
|
ASND
Ascendis Pharma AS
|
$165.99 | $210.61 | $10B | -- | $0.00 | 0% | 24.52x |
|
DBVT
DBV Technologies SA
|
$4.99 | $21.81 | $102.4M | -- | $0.00 | 0% | -- |
|
EVAX
Evaxion Biotech AS
|
$1.89 | $13.25 | $11.8M | -- | $0.00 | 0% | 0.52x |
|
VKTX
Viking Therapeutics
|
$28.95 | $99.29 | $3.2B | -- | $0.00 | 0% | -- |
|
ZLDPF
Zealand Pharma AS
|
$83.52 | -- | $5.9B | -- | $0.00 | 0% | 611.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
40.09% | 0.871 | 3.51% | 0.52x |
|
ASND
Ascendis Pharma AS
|
114.08% | 0.763 | 10.82% | 0.81x |
|
DBVT
DBV Technologies SA
|
-- | -0.036 | -- | -- |
|
EVAX
Evaxion Biotech AS
|
-- | -2.040 | -- | 2.80x |
|
VKTX
Viking Therapeutics
|
-- | -1.225 | -- | -- |
|
ZLDPF
Zealand Pharma AS
|
3.21% | 1.187 | 0.55% | 20.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
$10.4B | $5.2B | 60.28% | 86.85% | 40.78% | -$786.4M |
|
ASND
Ascendis Pharma AS
|
$170.4M | $408.3K | -69.61% | -880.05% | -24.36% | -$90.9M |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
EVAX
Evaxion Biotech AS
|
-- | -$1.7M | -238.97% | -- | -54.59% | -- |
|
VKTX
Viking Therapeutics
|
-- | -$46.2M | -- | -- | -- | -$31.2M |
|
ZLDPF
Zealand Pharma AS
|
$1.2M | -$56.6M | -16.68% | -17.27% | -3128.75% | -$24.9M |
Novo Nordisk AS vs. Competitors
-
Which has Higher Returns NVO or ASND?
Ascendis Pharma AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -22.12%. Novo Nordisk AS's return on equity of 86.85% beat Ascendis Pharma AS's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B ASNDAscendis Pharma AS91.94% -$0.68 $781.4M -
What do Analysts Say About NVO or ASND?
Novo Nordisk AS has a consensus price target of $113.54, signalling upside risk potential of 47.72%. On the other hand Ascendis Pharma AS has an analysts' consensus of $210.61 which suggests that it could grow by 26.88%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 4 1 ASNDAscendis Pharma AS12 1 0 -
Is NVO or ASND More Risky?
Novo Nordisk AS has a beta of 0.420, which suggesting that the stock is 58.038% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.413%.
-
Which is a Better Dividend Stock NVO or ASND?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.88%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or ASND?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Ascendis Pharma AS quarterly revenues of $185.4M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$41M. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.41x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.15x versus 24.52x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS8.15x 23.41x $12.2B $4B ASNDAscendis Pharma AS24.52x -- $185.4M -$41M
-
Which has Higher Returns NVO or DBVT?
DBV Technologies SA has a net margin of 32.95% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 86.85% beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About NVO or DBVT?
Novo Nordisk AS has a consensus price target of $113.54, signalling upside risk potential of 47.72%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 337.14%. Given that DBV Technologies SA has higher upside potential than Novo Nordisk AS, analysts believe DBV Technologies SA is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 4 1 DBVTDBV Technologies SA0 0 0 -
Is NVO or DBVT More Risky?
Novo Nordisk AS has a beta of 0.420, which suggesting that the stock is 58.038% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.
-
Which is a Better Dividend Stock NVO or DBVT?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.88%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or DBVT?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than DBV Technologies SA quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than DBV Technologies SA's net income of -$30.4M. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.41x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.15x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS8.15x 23.41x $12.2B $4B DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns NVO or EVAX?
Evaxion Biotech AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -64.14%. Novo Nordisk AS's return on equity of 86.85% beat Evaxion Biotech AS's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B EVAXEvaxion Biotech AS-- -$0.40 $74K -
What do Analysts Say About NVO or EVAX?
Novo Nordisk AS has a consensus price target of $113.54, signalling upside risk potential of 47.72%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 601.06%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 4 1 EVAXEvaxion Biotech AS1 0 0 -
Is NVO or EVAX More Risky?
Novo Nordisk AS has a beta of 0.420, which suggesting that the stock is 58.038% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NVO or EVAX?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.88%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or EVAX?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Novo Nordisk AS's net income of $4B is higher than Evaxion Biotech AS's net income of -$1.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.41x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.15x versus 0.52x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS8.15x 23.41x $12.2B $4B EVAXEvaxion Biotech AS0.52x -- $3M -$1.9M
-
Which has Higher Returns NVO or VKTX?
Viking Therapeutics has a net margin of 32.95% compared to Novo Nordisk AS's net margin of --. Novo Nordisk AS's return on equity of 86.85% beat Viking Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B VKTXViking Therapeutics-- -$0.32 -- -
What do Analysts Say About NVO or VKTX?
Novo Nordisk AS has a consensus price target of $113.54, signalling upside risk potential of 47.72%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 242.99%. Given that Viking Therapeutics has higher upside potential than Novo Nordisk AS, analysts believe Viking Therapeutics is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 4 1 VKTXViking Therapeutics9 1 0 -
Is NVO or VKTX More Risky?
Novo Nordisk AS has a beta of 0.420, which suggesting that the stock is 58.038% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.
-
Which is a Better Dividend Stock NVO or VKTX?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.88%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or VKTX?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Viking Therapeutics quarterly revenues of --. Novo Nordisk AS's net income of $4B is higher than Viking Therapeutics's net income of -$35.4M. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.41x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.15x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS8.15x 23.41x $12.2B $4B VKTXViking Therapeutics-- -- -- -$35.4M
-
Which has Higher Returns NVO or ZLDPF?
Zealand Pharma AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -3213.72%. Novo Nordisk AS's return on equity of 86.85% beat Zealand Pharma AS's return on equity of -17.27%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B ZLDPFZealand Pharma AS95.5% -$0.59 $1.2B -
What do Analysts Say About NVO or ZLDPF?
Novo Nordisk AS has a consensus price target of $113.54, signalling upside risk potential of 47.72%. On the other hand Zealand Pharma AS has an analysts' consensus of -- which suggests that it could fall by -73.06%. Given that Novo Nordisk AS has higher upside potential than Zealand Pharma AS, analysts believe Novo Nordisk AS is more attractive than Zealand Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 4 1 ZLDPFZealand Pharma AS0 0 0 -
Is NVO or ZLDPF More Risky?
Novo Nordisk AS has a beta of 0.420, which suggesting that the stock is 58.038% less volatile than S&P 500. In comparison Zealand Pharma AS has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.706%.
-
Which is a Better Dividend Stock NVO or ZLDPF?
Novo Nordisk AS has a quarterly dividend of $0.52 per share corresponding to a yield of 1.88%. Zealand Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Zealand Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or ZLDPF?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Zealand Pharma AS quarterly revenues of $1.3M. Novo Nordisk AS's net income of $4B is higher than Zealand Pharma AS's net income of -$41.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 23.41x while Zealand Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 8.15x versus 611.77x for Zealand Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS8.15x 23.41x $12.2B $4B ZLDPFZealand Pharma AS611.77x -- $1.3M -$41.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 24
Regencell Bioscience Holdings [RGC] is down 25.17% over the past day.
Buy
54
TNXP alert for Mar 24
Tonix Pharmaceuticals Holding [TNXP] is up 32% over the past day.
Sell
36
VMI alert for Mar 24
Valmont Industries [VMI] is up 4.37% over the past day.
